@SWOG
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- Web
Account-level information from X, not a live location or the device used for a specific post.
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956.
United States
Joined January 2012
- Tweets15.1K
- Following1.4K
- Followers14.6K
- Likes15.7K
SWOG Cancer Research Network retweeted
MAVERICK trial. This KM curve says it all. It's RIP for PCI in SCLC. @SWOG
Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm.
The end of the PCI era.
SWOG Cancer Research Network retweeted
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trials/s22… #mmsm #bmtsm
Read more about this new TrialMatch AI-assisted tool for finding cancer clinical trials for patients -- and about the study underway with @theMedNet and @SWOG testing whether the tool can raise awareness of trials and increase referrals:
swog.org/news-events/news/20…
I am committed to reducing administrative burdens related to cancer clinical trials. NCI SBIR-funded @theMedNet is helping with TrialMatch, a new AI-assisted tool that makes it faster and easier for doctors to find trials for their patients. go.nih.gov/uA0Cyg2
ALT Text on a beige background reads, \"TrialMatch. A better way to find cancer trials. Open, enrolling patients for the patient in front of you. Start a search. Funded by the National Cancer Institute.\"
SWOG Cancer Research Network retweeted
I am committed to reducing administrative burdens related to cancer clinical trials. NCI SBIR-funded @theMedNet is helping with TrialMatch, a new AI-assisted tool that makes it faster and easier for doctors to find trials for their patients. go.nih.gov/uA0Cyg2
ALT Text on a beige background reads, \"TrialMatch. A better way to find cancer trials. Open, enrolling patients for the patient in front of you. Start a search. Funded by the National Cancer Institute.\"
SWOG Cancer Research Network retweeted
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trials/s22… #mmsm #bmtsm
SWOG Cancer Research Network retweeted
I can’t wait to learn about the results of #S1827 in the presidential session on the first day of #WCLC2026 @IASLC @SWOG #PCI in Limited Stage SCLC & Extensive Stage SCLC Benefits, neurotoxicity, Early detection of lesions, role of MRI & SRS all are important questions.
2/6 MAVERICK / SWOG S1827
The question: in the MRI era, do patients with SCLC still need prophylactic cranial irradiation?
(both limited and extensive stage)
We know: PCI reduces brain metastases, but cognition and the role of modern MRI surveillance remain major concerns.
At WCLC: Can MRI surveillance safely replace PCI without compromising survival — and what happens to brain control, cognition and QoL?
This one could directly change practice.
Ovarian reserve as measure of adjuvant chemotherapy benefit in HR-positive, HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)
In premenopausal pts <55yrs, AMH was significantly better indicator of chemo benefit than menopause status, age
annalsofoncology.org/article…
Federal and Industry Sponsorship in US Cancer Clinical Trials
A comparative study of cancer clinical trial portfolios supported by federal versus industry funding characterizes their distinct, interdependent roles. In @JAMAOncology @drjoeunger @fredhutch
jamanetwork.com/journals/jam…
SWOG Cancer Research Network retweeted
🔥Measures of ovarian reserve could help refine selection to chemotherapy for patients with HR+, HER2-neg eBC
👉In RxPONDER, among premenopausal patients aged<55, those with low AMH levels did not benefit from chemotherapy
doi.org/10.1016/j.annonc.202…
SWOG Cancer Research Network retweeted
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trials/s22… #mmsm #bmtsm
SWOG Cancer Research Network retweeted
Final day of @SWOG Latin America Initiative @incanMX @SMEOMX symposium in Precision Oncology Research, Methods, and Data symposium in Mexico City. Congrats to the students and early career researchers selected to present their clinical trials proposals for in depth review and discussion! @Betzabe100 @anelcabrera
SWOG Cancer Research Network retweeted
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trials/s22… #mmsm #bmtsm
SWOG Cancer Research Network retweeted
The COMMIT Trial NRG-GI004 @SWOG S1610: Combination immunotherapy and chemotherapy improves progression-free survival for patients with metastatic dMMR colorectal cancer, via @EurekAlert! eurekalert.org/news-releases… @JCO_ASCO
SWOG Cancer Research Network retweeted
New in @JAMANetworkOpen: @SWOG S1600, a multicenter phase 3 RCT, found no reduction in 30- or 90-day complications w/ specialized immunonutrition vs standard nutrition after cystectomy. Exploratory DFS/OS favored immunonutrition. #BladderCancer
@JhamiltonReeves @DrJoeUnger @JMHolzbeierlein @FoxChaseCancer @BCM_Urology @JanetKukreja @eugenekanglee @URMCUrology @DrDawnHershman @fischmd @lynnhenrymd jamanetwork.com/journals/jam…
SWOG Cancer Research Network retweeted
Team effort! @SWOG @WinshipAtEmory
🆕article in press: Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) @KalinskyKevin
"If you're MET amplified, you could well consider S1900J ... That's for patients who have MET amplification at initial genomic testing."
- Marcia Horn, Chair, @METCrusaders
@LungMAP is a precision medicine trial testing treatments for advanced non-small cell lung cancer.
#NSCLC
SWOG Cancer Research Network retweeted
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trials/s22… #mmsm #bmtsm
SWOG Cancer Research Network retweeted
On this issue of ICI monotherapy versus combination with chemotherapy, the recently completed ECOG-SWOG phase 3 trial INSIGNA directly addresses this question in a randomized fashion. Also includes the PDL1 1-49% group Data analysis pending. @HosseinBorghaei @Annechiangmd @SWOG
🫁 Chemoimmunotherapy vs PD-(L)1 monotherapy.
A meta-analysis of 24 phase III trials (5,546 patients) found superior outcomes with chemoimmunotherapy over PD-(L)1 monotherapy in advanced NSCLC with PD-L1 ≥50%:
• OS: HR 0.85
• PFS: HR 0.61
Treatment selection should remain individualized.
📖 @JAMAOnc
DOI 👉🏻 doi.org/10.1001/jamaoncol.20…
#CánCare #NSCLC #lcsm #Immunotherapy #PDL1
SWOG Cancer Research Network retweeted
Let’s not forget the BRIGHT trial (@SWOG S2427) -Phase II study evaluating a bladder-preservation strategy for patients with #MIBC who achieve a meaningful response to neoadjuvant therapy—using pembrolizumab + radiation instead of immediate radical cystectomy in carefully selected patients. @l_ballas @AbhiTrip87 @MarkTysonMD @mouwlab @JoshMeeks @djmcconkey @KyleRoseMD @DrKarineTawagi @SeanSachdevMD @kritimittalmd
If a patient in front of you refuses RC after EVP, the honest answer is enrollment in a prospective surveillance protocol with predefined imaging and biopsy triggers for salvage therapy. (EV-209; NCT07475806)
NOT quiet endorsement of surveillance as standard of care.
@scserendipity1 @tompowles1 @AndreaNecchi @shilpaonc @siadaneshmand @UrogerliMD @bbmdmsk @joanfundi @IBCG_BladderCA @drenriquegrande @JoshMeeks